{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:01:44Z","timestamp":1785211304208,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijpx.2026.100559","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:51:10Z","timestamp":1777942270000},"page":"100559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A versatile and GMP-compliant bead-based IFN-\u03b3 potency assay for standardized quality control and release testing of CAR-T cell drug products"],"prefix":"10.1016","volume":"11","author":[{"given":"Robin","family":"Dennebos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Gonz\u00e1lez-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lysandrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke A.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G.W.","family":"Kosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm-Jan","family":"Lourens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahez","family":"Gareb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2026.100559_bb0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijpx.2026.100559_bb0010","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","article-title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial","volume":"108","author":"Asherie","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ijpx.2026.100559_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ijpx.2026.100559_bb0020","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/s41375-019-0418-8","article-title":"CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity","volume":"33","author":"Bueno","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ijpx.2026.100559_bb0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel Anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ijpx.2026.100559_bb0030","series-title":"Guideline on Quality, Non-Clinical and Clinical Aspects of Medicinal Products Containing Genetically Modified Cells. EMA\/CAT\/GTWP\/671639\/2008 Rev. 1 - corr","author":"Committee for Advanced Therapies (CAT)","year":"2020"},{"key":"10.1016\/j.ijpx.2026.100559_bb0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000518337","article-title":"The heterogeneity of response of PC12 cells from different laboratories to nerve growth factor and pituitary adenylate cyclase-activating polypeptide questions the reproducibility of studies carried out with tumor cell lines","volume":"113","author":"Delage","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ijpx.2026.100559_bb0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijpx.2026.100559_bb0045","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood-2010-10-311845","article-title":"In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor","volume":"117","author":"Giordano Attianese","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijpx.2026.100559_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.994532","article-title":"Standardized in-vitro evaluation of CAR-T cells using acellular artificial target particles","volume":"13","author":"Harari-Steinfeld","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41467-024-55340-5","article-title":"Genomic and phenotypic stability of fusion-driven pediatric sarcoma cell lines","volume":"16","author":"Kasan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100559_bb0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","article-title":"Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity","volume":"16","author":"Kiesgen","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ijpx.2026.100559_bb0070","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41375-021-01188-3","article-title":"Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia","volume":"35","author":"Kovalovsky","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ijpx.2026.100559_bb0075","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2025.2581615","article-title":"Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies","author":"Kulkarni","year":"2025","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ijpx.2026.100559_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41587-019-0037-y","article-title":"Multi-omic measurements of heterogeneity in HeLa cells across laboratories","volume":"37","author":"Liu","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ijpx.2026.100559_bb0090","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2026.100559_bb0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpx.2026.100559_bb0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/2277-8632.128412","article-title":"High-dose hook effect","volume":"3","author":"Namburi","year":"2014","journal-title":"J. Dr NTR Univ. Health Sci."},{"key":"10.1016\/j.ijpx.2026.100559_bb0105","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpx.2026.100559_bb0110","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","article-title":"Surface proteomics reveals CD72 as a target for in vitro \u2013evolved nanobody-based CAR-T cells in KMT2A\/MLL1 -rearranged B-ALL","volume":"11","author":"Nix","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijpx.2026.100559_bb0115","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ajh.26519","article-title":"Results of ARI-0001 CART19 cell therapy in patients with relapsed\/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease","volume":"97","author":"Ortiz-Maldonado","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ijpx.2026.100559_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae004","article-title":"Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells","volume":"4","author":"Patel","year":"2024","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.ijpx.2026.100559_bb0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.gene.2015.01.063","article-title":"MS-HRM assay identifies high levels of epigenetic heterogeneity in human immortalized cell lines","volume":"560","author":"Putnik","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.ijpx.2026.100559_bb0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor\u2013expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijpx.2026.100559_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-005-0085-6","article-title":"The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics","volume":"21","author":"Sambuy","year":"2005","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0150","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijpx.2026.100559_bb0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijpx.2026.100559_bb0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ijpx.2026.100559_bb0165","series-title":"ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products (CPMP\/ICH\/365\/96)","author":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"1999"},{"key":"10.1016\/j.ijpx.2026.100559_bb0170","series-title":"ICH Q2(R2) Guideline on Validation of Analytical Procedures (EMA\/CHMP\/ICH\/82072\/2006)","author":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2023"},{"key":"10.1016\/j.ijpx.2026.100559_bb0175","series-title":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.ijpx.2026.100559_bb0180","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpx.2026.100559_bb0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13045-021-01160-9","article-title":"Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0190","article-title":"Artificial targets: a versatile cell-free platform to characterize CAR T cell function in vitro","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-95903-0","article-title":"Jurkat T-cell lines exhibit marked genomic instability affecting karyotype, mutational profile, gene expression, immunophenotype and function","volume":"15","author":"Wilson","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2026.100559_bb0200","article-title":"Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpx.2026.100559_bb0205","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1182\/bloodadvances.2025017873","article-title":"Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity","volume":"9","author":"Yoo","year":"2025","journal-title":"Blood Adv."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156726000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:45:51Z","timestamp":1785210351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156726000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"alternative-id":["S2590156726000794"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100559","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A versatile and GMP-compliant bead-based IFN-\u03b3 potency assay for standardized quality control and release testing of CAR-T cell drug products","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2026.100559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100559"}}